1990-2011 were retrospectively reviewed. Survival was estimated using the Kaplan-Meier method; 48 associated prognostic factors were assessed using Cox's model.
49
RESULTS: Of 153 cases of metastatic DTC, 59% (n=91) met a criterion for RR: i.e., 60% (n=55) 50 had at least one metastasis without 131 
99
RR status were excluded from the study (Figure 1 ).
100
Radiological reports were used to define progressive disease as closely as possible to RECIST 
279
However, the study of Tg-DT has several difficulties, particularly dosage interference caused by 280
TgAb; therefore, our results should be validated in a larger prospective cohort.
281
Numerous authors have studied the survival and prognostic factors for metastatic DTC; 282 however, few authors have focused specifically on RR-DTC. Moreover, data provided by clinical 283 trials often suffer from a short follow-up, which limits the ability to identify prognostic factors for OS.
284
Despite some limitations, to our knowledge, this is the largest published "real-life" series using the 
315
A large study with sequential biopsies of DM could improve our understanding of the biological 316 phenomena underlying the evolution of RR-DTC.
317
In conclusion, this study could improve assessment of the prognosis of RR-DTC patients and 318 thus the selection of an optimum therapeutic strategy: i.e., an aggressive treatment with a systemic 319 therapy for those with a worse prognosis or active surveillance for those with a better prognosis.
320
External validation of these findings and further exploration into the prognosis of RR-DTC, including 321 molecular biology, are warranted. 
